What is new in the world of imaging?
In this article, Drug Target Review’s Hannah Balfour discusses three of the latest developments in imaging for disease research and drug development.
List view / Grid view
In this article, Drug Target Review’s Hannah Balfour discusses three of the latest developments in imaging for disease research and drug development.
Using a new compound mixture, researchers have created adaptive and regenerative stem cells from human fat cells.
A new study shows that upregulating the activity of the ACE2 signalling pathway in kidney cancer cells enhances the effects of clinically used treatments.
A new form of CAR T-cell therapy has shown promise in mice models to treat blood cancers; this article delves into the development behind the therapy.
A single change to the structure of bacterial ribosomes prevents macrolide antibiotics from binding and killing the bacteria, according to a study.
Researchers show selectively activating androgen receptors could be an effective treatment for oestrogen receptor positive breast cancers.
Treating only a few nerve cells with the hyper-interleukin-6 (hIL-6) gene therapy stimulated the regeneration of nerves.
Researchers have isolated a compound from I. viscosa that kills the "brain-eating" amoebae from primary amoebic meningoencephalitis (PAM).
By combining nanobodies targeting different regions of the SARS-CoV-2 Spike protein, researchers were able to protect cells from infection.
Scientists have developed an inhaled treatment for asthma that prevents excess mucus from building up in mice.
Tests in Alzheimer's disease mouse models have shown that hydrogen sulphide can improve cognitive and motor function by 50 percent.
Understanding how Staphylococcus aureus bacteria colonises skin affected by atopic dermatitis could lead to new treatments that help prevent the spread of antibiotic resistance, say scientists.
Scientists show that an antibody targeting a protein acting as a viral toxin, can prevent the dengue virus from infecting human cells.
Inhibiting the ACSS2 enzyme with a molecule called VY-3-135 caused a significant reduction in the growth of breast cancer tumours in vivo.
Dr H. Michael Shepard, CEO and CSO of Enosi Life Sciences, discusses the similarities between cancer and autoimmune diseases, highlighting how this knowledge could be used to enhance treatments.